CHA2DS2-VASc评分对急性心肌梗死患者行冠状动脉介入治疗无复流现象预测

目的 本研究旨在验证CHA2DS2 VASc评分对直接经皮冠状动脉介入治疗（PCI）的ST段抬高型心肌梗死（STEMI）患者无复流现象的临床预测价值。方法 将我院收治接受原发性PCI治疗的300例STEMI患者分为两组：将27例无复流患者作为第一组,将其余273例患者作为对照组。计算每例患者CHA2DS2 VASc风险评分。结果 CHA2DS2 VASc评分与无复流相关性的多变量分析差异有统计学意义（P<0.05）。CHA2DS2 VASc评分中各个成分对无复流预测能力差异有统计学意义（P<0.05）。结论 在接受PCI治疗的STEMI患者中,较高的CA2DS2 VASc评分与无复流现象风险和住院病死率相关。

Prediction of no reflow phenomenon in patients with acute myocardial infarction undergoing coronary intervention by CHA2DS2 VASc score

Objective To verify the clinical predictive value of CHA2DS2 VASc score in the absence of reflow in ST segment elevation myocardial infarction (STEMI) patients after direct percutaneous coronary intervention (PCI). Methods 300 STEMI patients admitted to our hospital for primary PCI were divided into two groups: 27 patients without reflow as the first group, and the remaining 273 patients as the control group. CHA2DS2 VASc risk score was calculated for each patient.Results There was statistically significant difference in multivariate analysis between CHA2DS2 VASc score and non reflow correlation (P<0.05).The components of CHA2DS2 VASc score showed significant differences in the prediction ability of non reflow(P<0.05). ConclusionIn STEMI patients treated with primary PCI, higher CHA2DS2 VASc score was associated with the risk of no reflow and in hospital mortality.